who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Chris Howard of Softeq, Stephanie Hertzog of Sodexo, and Moody Heard of Buildforce. Courtesy photos

Editor's note: In the week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — oil and gas, tech development, and construction staffing — recently making headlines in Houston innovation.


Chris Howard, CEO of Softeq

On this week's episode of the Houston Innovators Podcast, Softeq Founder and CEO Chris Howard shares how he's focusing on supporting the Houston innovation ecosystem. Photo courtesy of Softeq

A sign of a blossoming innovation ecosystem is when experienced and successful founders turn their focus to supporting emerging startups. That's what Chris Howard, who founded his tech company over 20 years ago, is looking to do with a new innovation lab and more in the works.

"I want to give back as an entrepreneur and a Houstonian," Howard says on this week's episode of the Houston Innovators Podcast. "I really want to leverage Softeq's expertise in order to help these companies grow in the same way that we've been doing for a couple of decades now."

Howard shares more about the Softeq Innovation Lab and how COVID-19 has affected his business and technology in general on the episode. Click here to read more and stream the episode.

Stephanie Hertzog, CEO of Sodexo

Stephanie Hertzog is hoping the future workforce of her company and others within the energy industry better reflects the city's diverse populations. Photo courtesy of Sodexo

Ever since taking the helm at Houston-based Sodexo Energy Resources North America, CEO Stephanie Hertzog has been intentional with prioritizing diversifying the workforce of the company. In a Q&A with InnovationMap, she notes on how the energy industry has been known as pretty homogeneous, especially within the gender divide. But things are changing.

"And we need to all be focusing on getting more of not only diversity, but inclusion as well," she says. "It's not just about hiring a diverse group, it's about making those people feel included when they get here and having them want to stay and be a part of our industry." Read more.

Additionally this week, Hertzog expands on her call for the energy industry to diversify in a guest column for InnovationMap. Click here to read it.

Moody Heard, CEO of BuildForce

Houston-based Buildforce is developing a technology to better connect contractors and the trade professionals they employ. Photo courtesy of Buildforce

A Houston innovator is tapping into tech to disrupt a booming industry in Houston, Texas, and beyond .Buildforce is a construction staffing app that aims to more efficiently connect contractors to skilled workers in trades ranging from electrical, mechanical, and plumbing to flooring, concrete, painting, and more.

The company raised a $1.5 million pre-seed round led by Houston-based Mercury Fund and is led by CEO Moody Heard.

"Our key insight is that providing a superior service to construction employers starts with providing a superior experience for tradesmen and women," Heard says in a news release. "Talent is the greatest finite resource in construction in Texas. In order to deliver talent to our contractor partners, we've created a job placement experience that is simple, friendly, and transparent. That's something people in the construction trades aren't used to, and has helped us grow incredibly quickly over the past several months." Click here to read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News